LUND,
Sweden, Nov. 11, 2022 /PRNewswire/ -- Immunovia, a
diagnostic company with the vision to revolutionize blood-based
diagnostics and survival rates for patients with cancer, announces
its financial calendar for 2023 and 2024.
|
February 9,
2023
|
Year-end report
2022
|
|
April 25,
2023
|
Q1 2023
|
|
August 24,
2023
|
Q2 2023
|
|
November 9,
2023
|
Q3 2023
|
|
February 21,
2024
|
Year-end report
2023
|
The Annual General Meeting will be held on April 27, 2023.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information see:
www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
The following files are available for download:
|
https://mb.cision.com/Main/13121/3665920/1666616.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/immunovia-announces-the-financial-calendar-for-financial-year-2023-301675804.html
SOURCE Immunovia AB